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EnvelopeDuring the course of at least 50% of HIV-1 subtype B infections, CCR5-using (R5) viruses evolve towards a
CXCR4-using phenotype. To gain insight in the transition from CCR5 to CXCR4 coreceptor use, we investigated
whether acquisition of CXCR4 use in vitro of R5 viruses from four patients resembled this process in vivo. R5
variants from only one patient acquired CXCR4 use in vitro. These variants had envelopes with higher V3
charge and higher number of potential N-linked glycosylation sites when compared to R5 variants that failed
to gain CXCR4 use in vitro. In this patient, acquisition of CXCR4 use in vitro and in vivo was associated with
multiple mutational patterns not necessarily involving the V3 region. However, changes at speciﬁc V3
positions were prerequisite for persistence of CXCR4-using variants in vivo, suggesting that positive selection
targeting the V3 loop is required for emergence of CXCR4-using variants during natural disease course.t of Experimental Immunology,
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Cell tropism and coreceptor use of human immunodeﬁciency virus
type-1 (HIV-1) variants are determined by the viral envelope (env)
glycoprotein gp120, which binds to CD4 and a coreceptor (Alkhatib
et al., 1996; Ashorn et al., 1990; Berson et al., 1996; Clapham et al.,
1994; Dalgleish et al., 1984; Deen et al., 1988; Feng et al., 1996;
Klatzmann et al., 1984; Maddon et al., 1986; Trkola et al., 1996; Wu
et al., 1996). The main coreceptors used by HIV-1 in vivo are the
chemokine receptors CCR5 and CXCR4 (Bleul et al., 1996; De Roda
Husman et al., 1999; Deng et al., 1996; Doranz et al., 1996; Dragic
et al., 1996; Feng et al., 1996). Additionally, HIV-1 can use other
coreceptors such as CCR2b, CCR3, CCR8, CXCR6, gpr1, RDC1 and APJ
although their role in vivo is still not clearly deﬁned (Bjorndal et al.,
1997; Choe et al., 1996; Deng et al., 1997; Doranz et al., 1996; Edinger
et al., 1998; Rucker et al., 1997; Shimizu et al., 2000, 2009; Zhang et al.,
1998a,b).
CCR5-using (R5) viruses predominate in the early stages of
infection and persist throughout the course of the disease (Connor
et al., 1997; Scarlatti et al., 1997; Schuitemaker et al., 1992). Inapproximately half of HIV-1 subtype B infected individuals, viruses
capable of using CXCR4 emerge prior to AIDS diagnosis, preceding a
more rapid CD4+ T cell decline and accelerated disease progression
(Brumme et al., 2005; Connor et al., 1997; Karlsson et al., 1994; Koot
et al., 1993, 1996; Moyle et al., 2005; Richman and Bozzette, 1994;
Schuitemaker et al., 1992). The mechanism underlying the evolution
towards a CXCR4-using phenotype is still not fully understood. Better
insight in this process has become even more relevant as the
acquisition of CXCR4 use by R5 variants has negative implications
for the treatment with CCR5 inhibitors that are now entering clinical
trials or that are already available as therapy option (Gulick et al.,
2007, 2008). Different selective pressures could play a role in the
emergence of CXCR4-using variants such as host neutralizing
antibodies (nAbs) and cytotoxic T cell (CTL) responses directed
against the env protein, target cell availability, chemokine levels in
plasma and coreceptor expression levels (Bunnik et al., 2007; De Roda
Husman et al., 1997; Safrit et al., 1994).
Determinants of coreceptor use have been mapped in V3 and V1/
V2 gp120 env variable regions (Boyd et al., 1993; Carrillo and Ratner,
1996a; Chesebro et al., 1996; Cocchi et al., 1996; Fouchier et al., 1992;
Hwang et al., 1991; Jansson et al., 2001; Labrosse et al., 2001; Nabatov
et al., 2004; Pastore et al., 2006; Schuitemaker et al., 1995; Shioda
et al., 1991) and less frequently in other gp120 regions (Carrillo and
Ratner, 1996b; Hoffman et al., 2002; Hu et al., 2000a,b; Kim et al.,
1995; Smyth et al., 1998), and in the fusion peptide gp41 (Huang et al.,
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accomplished via multiple mutational pathways, some common
features such as the presence of positively charged amino acids at
positions 11 and/or 25 of the V3 loop have been associated with
CXCR4 use in HIV-1 subtype B (De Jong et al., 1992; Fouchier et al.,
1992, 1995), and negatively charged or uncharged amino acids at
positions 11, 25 or 28/29, resulting in low V3 charge, or presence of a
glycine-proline-glycine (GPG) motif at positions 15–17 have been
associated with CCR5 use (De Jong et al., 1992; Fouchier et al., 1992;
Hu et al., 2000a,b; Shioda et al., 1992). Given the high mutation rate
and rapid viral turnover of HIV-1, and considering that only few
amino acid changes in the V3 loop are sufﬁcient for a switch from
CCR5 to CXCR4 coreceptor use (Chesebro et al., 1996; Cordonnier et
al., 1989; De Jong et al., 1992; Harrowe and Cheng-Mayer, 1995;
Mosier et al., 1999; Shimizu et al., 1999; Shioda et al., 1992),
emergence of CXCR4-using variants would be expected to occur
rapidly and relatively early in the course of infection. However, in a
signiﬁcant fraction of subtype B infected individuals CXCR4-using
variants are never detected throughout the disease course (Koot et al.,
1993, 1999), which suggests that intrinsic obstacles like replication
ﬁtness, efﬁciency of coreceptor use and evasion of the immune
response may interfere with the emergence of CXCR4-using variants
in vivo.
To increase our understanding of the underlying mechanism of
transition from CCR5 to CXCR4 coreceptor use, we investigated
whether acquisition of CXCR4 coreceptor use of primary R5 viruses in
vitro resembled the process that had occurred in vivo. To this end, R5
variants from four patients in whom CXCR4-using variants emerged
during their disease course, and a molecular CCR5-using HIV-1 clone,
were cultured in U87 cells expressing CD4 and CCR5 (U87.CD4.CCR5)
in the presence of increasing percentages of U87 cells expressing CD4
and CXCR4 (U87.CD4.CXCR4), as previously described by Pastore et al.
(2004). In this culture system, CXCR4-using variants that may emerge
by chance will be selected due to the replication advantage created by
the presence of CXCR4-positive target cells (Pastore et al., 2004).
Subsequently, viral gp120 env sequences from R5 and CXCR4-using
HIV-1 variants longitudinally isolated throughout natural disease
course prior to and after in vivo emergence of CXCR4-using viruses
were compared to gp120 env sequences from R5 HIV-1 variants that
had acquired CXCR4 coreceptor use in vitro in U87.CD4.CCR5/U87.
CD4.CXCR4 cocultures. By comparing evolution from CCR5 towards
CXCR4 use in vivo and in an in vitro system based on limiting amounts
of CCR5 and increasing amounts of CXCR4 coreceptors, we intend to
assess whether all primary R5 variants have the same ability to
acquire CXCR4 use and whether coreceptor and target cell availability
is indeed sufﬁcient to drive this process.
Results
In vitro evolution towards a CXCR4-using phenotype of molecular clone
NL4.3-BaL and primary clonal R5 HIV-1 variants
We ﬁrst determined whether clonal R5 HIV-1 variants from HIV-1
infected individuals in whom CXCR4-using variants emerged during
the natural course of infection had the ability to acquire CXCR4 use in
vitro. The CCR5-using molecular clone NL4.3-BaL was used for
comparison, as in vitro evolution from CCR5 to CXCR4 coreceptor use
of the CCR5-using BaL envelope has previously been demonstrated
(Pastore et al., 2004).
In two independent experiments run at the same time, ﬁve parallel
cultures of U87.CD4.CCR5 cells were inoculated with NL4.3-BaL and
serial passage of the culture supernatants onto mixed cultures of U87.
CD4.CXCR4 cells and over time decreasing percentages of U87.CD4.
CCR5 cells was performed. In each of the two parallel experiments, in
4 of the 5 parallel cultures, a pronounced decrease in viral replication,
as reﬂected by a decrease in p24 production, was observed when theproportion of U87.CD4.CCR5 cells was reduced to 5–10% (Fig. 1A). In
both experiments, in 2 of these 4 cultures, virus replication increased
at day 35 when the proportion of U87.CD4.CCR5 cells was only 0.2%,
suggesting that the virus in these cultures had at that time gained the
ability to replicate in U87.CD4.CXCR4 cells. Indeed, when super-
natants from these cultures were transferred to cultures with only
U87.CD4.CXCR4 cells, p24 production could be detected within 7 days
(Fig. 1A). In 1 of the 5 parallel cultures in each of the two experiments
with NL4.3-BaL, viral replication moderately declined when the
proportion of U87.CD4.CCR5 cells was reduced to 10%, and after
that, a stabilization or even a rapid increase of the viral replication
levels was observed, indicating that the viruses in these single
cultures had acquired the ability to use CXCR4 already within the ﬁrst
20 days after the onset of the experiment (Fig. 1A).Overall, the gain of
CXCR4 use was observed in 60% (3 out of 5) of the cultures inoculated
with NL4.3-BaL in both experiments.
Eighteen primary clonal R5 HIV-1 variants isolated from four
patients prior to and after estimated in vivo emergence of CXCR4-
using viruses (4–6 clonal R5 variants per study subject) were tested
for their ability to gain CXCR4 use in vitro. Six parallel cultures of U87.
CD4.CCR5 cells were inoculated per R5 clonal HIV-1 variant and they
were subjected to the same serial passages as NL4.3-BaL. The clonal R5
variants from only one patient (patient 4) acquired the ability to use
CXCR4 in vitro (RO-B2 and RO-B4, RO-G1 and RA-H7, obtained
2 months prior to, or 10 or 19 months after the estimated date of ﬁrst
appearance of CXCR4-using variants in vivo), as reﬂected in their
ability to replicate in cocultures of U87.CD4.CXCR4 cells and 0.2% U87.
CD4.CCR5 cells (Fig. 1B). For RO-B2, RO-B4 and RO-G1, this was
observed in 1, 2, and 1 out of 6 parallel cultures, respectively. Even
then, only the progeny virus variants from RO-B2 and RO-G1 were
able to replicate in U87.CD4.CXCR4 cells in the absence of U87.CD4.
CCR5 cells (Table 2). In contrast, clonal R5 variant RA-H7 very
efﬁciently gained the ability to use CXCR4 in vitro: virus replication
could be detected in 5 out of 6 parallel cocultures of U87.CD4.CXCR4
cells with only 0.2% U87.CD4.CCR5 cells and all progeny viruses were
able to replicate in cultures of only U87.CD4.CXCR4 cells and in MT-2
cells (Table 2). However, none of the in vitro progeny viruses of RO-B2,
RO-G1 and RA-H7 had the ability to replicate in PBMC from CCR5Δ32
homozygous donors (Table 2). All in vitro evolved CXCR4-using
variants still had the ability to replicate in U87.CD4.CCR5 cells
(Table 2).
Analysis of gp120 env gene mutations in in vitro CXCR4-using progeny of
NL4.3-BaL
Sequence comparison of NL4.3-BaL and its 6 CXCR4-using progeny
virus variants revealed that 67–100% of the amino acid substitutions
per variant occurred in the variable domains V2, V3 and V4. Although
several different patterns of mutation were observed in these variable
regions, most of them involved the substitution of a negatively
charged or neutral amino acid by a positively charged amino acid
(Supplementary Table A1). Three of the 6 in vitro evolved CXCR4-
using progeny of NL4.3-BaL gained a positively charged amino acid (K
or R) at position 11 or 25 in the V3 region, whereas in the other three
the Proline (P) at the tip of the V3 loop was substituted by Arginine
(R) or Serine (S) (Supplementary Table A1). The accumulation of
positively charged amino acids in HIV-1 env has previously been
associated with in vivo or in vitro acquisition of CXCR4-usage of HIV-1
(Fouchier et al., 1992; Pastore et al., 2004).
Genetic comparison of CXCR4-using variants that have evolved either in
vivo or in vitro
We next assessed whether in vitro evolved CXCR4-using variants
genetically resembled the CXCR4-using variants that had emerged in
patient 4 in vivo. Gp120 (C1–C4) env sequences from R5 and in vivo
Fig. 1. Replication kinetics of NL4.3-BaL (A) and clonal R5 variants from patient 4 (B) during in vitro culturing in U87.CD4.CCR5 cells with increasing percentages of U87.CD4.CXCR4
cells. Virus replication is measured by p24 production in the culture supernatant. Grey arrows specify the p24 value obtained from U87.CD4.CXCR4 cells containing the indicated
percentage of U87.CD4.CCR5 cells.
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phylogenetically analyzed using a ML tree (Fig. 2).
Tree topology showed that the majority of in vivo evolved CXCR4-
using variants (12 of 16) clustered together, segregating from the R5
variants. However, four CXCR4-using variants that were isolated
10 months and 19 months after the estimated date of in vivo
emergence of CXCR4-using variants intermingled with R5 variants,
thus revealing the presence in this patient of variants with R5-like
sequences with the ability of using CXCR4 (Fig. 2). Indeed, based on
their V3 amino acid sequences all 4 variantswere predicted to be R5 by
the PSSMNSI/SI (Jensen et al., 2003, 2006) and the geno2pheno[coreceptor]
(FRP=5%)method (Sing et al., 2007) (data not shown), yet CXCR4 use
of these four variants could be conﬁrmed by their ability to
productively infect MT-2 cells and PBMC from CCR5Δ32 homozygous
donors at comparable levels than the rest of CXCR4-using variants of
patient 4 (data not shown). In a separate study we showed that the 12
in vivo CXCR4-using variants belonging to the main cluster of CXCR4-
using sequences were the variants that were able to persist and
generate progeny virus in peripheral blood even though their
efﬁciency in CXCR4 use did not differ from the CXCR4 use efﬁciency
of the four in vivo CXCR4-using variants with an R5-like sequence
(Edo-Matas et al., 2010).
As compared to R5 variants, the only unique amino acid differences
found for the in vivo evolved CXCR4-using variants that successfully
established infection in peripheral blood in patient 4 were at positions
11 and 24 in the V3 region (Edo-Matas et al., 2010; data not shown).Those in vivo evolved CXCR4-using variants had a positively charged
amino acid (R) at position 11 and a Glutamic acid (E) (or Arginine (R)
in one variant) at position 24 while R5 variants had a Glycine (G) or a
Serine (S) at position 11 and a Glycine (G) at position 24. The four in
vivo evolved CXCR4-using variants that genetically resembled R5
variants and which did not result in CXCR4-using progeny in vivo had
the same amino acids as R5 variants at positions 11 and 24 of the V3
region (S/G and G, respectively).
In vitro evolved CXCR4-using variants clustered together with their
parental clonal R5 variants revealing that they are genetically highly
similar. Sequence analysis showed that in vitro evolved CXCR4-using
variants differed from their respective parental R5 clonal variants at
one to ten amino acid positions that were not restricted to a speciﬁc
region of gp120. In in vitro evolved CXCR4-using variants RO-B2.1-1
and RO-G1.3-1, a total of respectively three and six amino acid
changes were observed in gp120 (Table 3 and Supplementary Table
A2). The ﬁve in vitro evolved CXCR4-using variants from parental R5
variant RA-H7 (RA-H7.4-2, RA-H7.4-3, RA-H7.4-4, RA-H7.4-5 and
RA-H7.4-6), had a variable number of mutations, ranging from one
mutation in RA-H7.4-2, to a total of six to ten mutations in the other
progeny viruses (Table 3). Althoughmostmutations were unique for a
single in vitro evolved CXCR4-using variant, substitution F20I in V3,
N28K in V4, and S22R in C4 were observed in 3, 3 and 4 RA-H7
progeny viruses respectively; T5I in V5 was present in all RA-H7
progeny viruses and in RO-G1.3-1 and V18I in C5 was found in 1
RA-H7 progeny virus and in RO-G1.3-1 (Table 3). Only two in vitro
Table 1
Clonal R5 HIV-1 variants for in vitro evolution from CCR5 to CXCR4 coreceptor use
experiment.
Patient Cohort ID Months
after SC
Months
to X4a
Virus U87b MT-2c Δ32c
1 18839 5 −56 C1 R5 – –
G11 R5 – –
70 8 D5 R5 – –
A5 R5 – –
2 18880 10 −35 20 R5 – –
39 R5 – –
29 −16 65 R5 – –
56 R5 – –
65 19 3F3 R5 – –
3G6 R5 – –
3 19308 3 −36 F8I R5 – –
D1 R5 – –
29 −10 D7 R5 – –
D11 R5 – –
53 14 A11 R5 – –
H7 R5 – –
4 19829 60 −2 RO-B2 R5 – –
RO-B4 R5 – –
72 10 RO-G1 R5 – –
81 19 RA-H7 R5 – –
SC: seroconversion.
a Time to emergence of CXCR4-using variants (estimated date between last negative
and ﬁrst positive MT-2 test).
b Co-receptor usage determined on U87.CD4.CCR5 and U87.CD4.CXCR4.
c Ability of the virus to replicate in MT-2 cells and PHA-stimulated PBMC from
CCR5Δ32 homozygous donors.
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acids in the V3 region: in RO-G1.3-1 a G17R, which has previously
been associated with in vitro gain of CXCR4 use (Pastore et al., 2004),
and G24R in RA-H7.4-5. Gain of positively charged amino acids
outside the V3 region, particularly in C1, V1, V4 and C4 regions, was
observed in in vitro evolved CXCR4-using progeny of RA-H7. Nine of
the overall 31 amino acid substitutions observed in in vitro evolved
CXCR4-using variants resulted in the loss of a Potential N-linked
Glycosylation Site (PNGS) of which T5I in V5 is shared by the progeny
of both RO-G1 and RA-H7.
Only six of the 31 mutations identiﬁed between the parental R5
variants and their in vitro evolved CXCR4-using progeny were shared
with in vivo evolved CXCR4-using variants and only one of them (R at
position 24 of the V3 region of RA-H7.4-5) was found to be unique for
the in vivo evolved CXCR4-using variants that were able to persist and
generate CXCR4-using progeny virus in peripheral blood and absent in
the R5 variants and the four CXCR4-using variants that did not persist.
From these observations we can conclude that for the R5 variants
from patient 4, multiple mutational patterns, not necessarilyTable 2
Cellular tropism of in vitro evolved CXCR4-using variants.
Patient Virus Months
after SC
Months
to X4a
Clone
nr
U87.CD4.
CCR5b
U87.CD4.
CXCR4b
MT-2b Δ32b
4 RO-B2 60 −2 1-1 + + − −
RO-B4 60 −2 2-3 + − − −
2-6 + − − −
RO-G1 72 10 3-1 + + − −
RA-H7 81 19 4-1 + − − −
4-2 + + + −
4-3 + + + −
4-4 + + + −
4-5 + + + −
4-6 + + + −
SC: seroconversion.
a Time to emergence of CXCR4-using variants (estimated date between last negative
and ﬁrst positive MT-2 test).
b Ability of the virus to replicate in U87.CD4.CCR5, U87.CD4.CXCR4, MT-2 cells and
PHA-stimulated PBMC from a CCR5Δ32 homozygous donors.restricted to the V3 region, are associated with the acquisition of
CXCR4 use in vitro and in vivo, but only a single mutation pattern
involving changes at V3 positions 11 and 24 is associated with the
gain of CXCR4 use of the HIV-1 variants that successfully gave rise to
CXCR4-using progeny in vivo.
Comparison of envelope molecular properties of R5 variants that do or
do not acquire CXCR4 use in vitro
To assess whether differences in envelope molecular properties
could explain why only R5 variants from one of the four patients had
the ability to acquire CXCR4 use in vitro, the charge of the V3 region
and the number of Potential N-linked Glycosylation Sites (PNGS) in
the gp120 (C1–C4) env region were compared between the R5
variants from patient 4, which had the ability to gain CXCR4-use in
vitro, and R5 variants from the other 3 patients, which lacked that
ability. For patient 4, the V3 charge of R5 variants RO-B2, RO-G1, and
RA-H7 varied between 5.6 and 6.6, which was signiﬁcantly higher
than for the other 3 patients (Fig. 3A). The number of PNGS in the
gp120 (C1–C4) env region of the three R5 variants of patient 4 varied
between 29 and 30, which was signiﬁcantly higher than the R5
variants from the other three patients (Fig. 3B).
Discussion
Many studies have shown the in vitro evolution of CCR5 to CXCR4
coreceptor use of R5 laboratory adapted strains, either by target cell
selection (Dejucq et al., 2000; Kiselyeva et al., 2007; Moncunill et al.,
2008; Pastore et al., 2004, 2006) or by CCR5 inhibition (Kiselyeva
et al., 2007; Marozsan et al., 2005; Moncunill et al., 2008; Mosier et al.,
1999), both systems based on limiting CCR5 availability to drive this
process. However, no comparison with the in vivo evolution of
coreceptor use in the corresponding patients was reported. Here,
using the approach of target cell selection, we for the ﬁrst time studied
the ability of primary R5 variants, isolated prior to and after in vivo
emergence of CXCR4-using variants from four HIV-1 infected
individuals, to gain CXCR4 use in vitro, and compared this to the in
vivo evolution from CCR5 to CXCR4 use of HIV-1 variants from those
same patients.
The study of Pastore et al. (2004) showed that the R5 HIV-1 strains
242 and JR-CSF acquired CXCR4 use by in vitro target cell selection
within 8 to 20 days and that for the R5 ADA and BaL strains that
process took approximately 40 days. NL4.3-BaL, used here as a
reference strain, gained the ability to use CXCR4 within the ﬁrst
35 days of in vitro culture in a similar system. Acquisition of CXCR4
usage was, however, far less successful for the 18 primary clonal R5
HIV-1 variants from four HIV-1 infected individuals as only R5
variants tested from patient 4 successfully gained CXCR4 use in vitro,
and only after 35 to 60 days after the onset of the experiment. These
data suggest that in the absence of the host selective pressures that
are present in vivo, evolution to a CXCR4-using phenotype of primary
R5 viruses is difﬁcult and that limiting amounts of CCR5 and abundant
CXCR4 are not always sufﬁcient to drive this process.
CXCR4-using HIV-1 variants generally have a more positively
charged V3 env region than CCR5-using variants (De Jong et al., 1992;
Fouchier et al., 1992, 1995). Interestingly, the R5 variants of patient 4
that successfully acquired CXCR4 use in vitro had more positively
charged V3 regions than the R5 variants of the other 3 patients that
failed to evolve to a CXCR4-using phenotype in vitro. Moreover,
analysis of envelope molecular properties of co-existing R5 and
CXCR4-using HIV-1 before and after the emergence of CXCR4-using
variants in 12 HIV-1 infected individuals (Edo-Matas et al., 2010),
including the four patients studied here, showed that V3 regions from
CXCR4-using variants from all patients but patient 4 were more
positively charged than the V3 regions from their co-existing R5
variants. In contrast, for patient 4, this was only observed for the
Fig. 2. Maximum-likelihood tree of gp120 (C1–C4) env R5 and in vivo and in vitro evolved CXCR4-using variants sequences from patient 4. ML tree was rooted using the root that
maximized the correlation of root-to-tip divergence as a function of sampling time. Bootstrap support N70% is shown. R5 variants (black). In vivo evolved CXCR4-using variants
(grey). Parental R5 variants are indicated between brackets. Names of in vitro evolved CXCR4-using variants are indicated in the tree. The scale bar (horizontal line) indicates branch
length corresponding to 0.01 substitutions per site.
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positive MT-2 test based on bulk PBMC. V3 regions from CXCR4-
using variants isolated after that time point had a similar or even
lower charge than V3 regions from the co-existing R5 variants, which
were much more positively charged (average charge between 5.35
and 5.7) than the V3 regions of R5 variants of the other 9 patients
(average charge b5.1).
The fact that only the R5 variants from patient 4 were able to gain
CXCR4 use in vitro in combination with the observation that in this
patient ﬁve independent events of acquisition of CXCR4 use occurred in
vivowhile generally only one event is observed in most patients (Edo-
Matas et al., 2010), may suggest that a more positively charged V3
region in a R5 variant favors the transition from CCR5 to CXCR4 use. In
addition, in patient 4 amino acid differences between R5 and in vivo
evolved CXCR4-using variants were restricted to the V3 region, while
differences in other regions (V1, V2, C3, V4, C4) besides V3 were
observed in the other three patients (Edo-Matas et al., 2010). The
potential requirement for a higher number of mutations in order to
acquire CXCR4 use in vivo in patients 1, 2 and 3, provides a possible
explanation for the inability of their R5 variants to acquire CXCR4 use in
vitro. The R5 variants of patient 4 that successfully gained CXCR4 use in
vitro also had a higher number of PNGS in gp120 as compared to the R5variants from the other 3 patients. Whether those envelope character-
istics are causally related to the ability to acquire CXCR4 use in vitro and
vivo remains to be established.
Interestingly, the R5 variant from patient 4 isolated 19 months after
the estimated in vivo emergence of CXCR4-using variants, more readily
gained CXCR4 use in vitro than the R5 variants isolated from time points
closer to the estimated in vivo emergence of CXCR4-using variants. This
could imply that the envelope of later stage R5 variants that have co-
existed with the CXCR4-using variants is genetically, and perhaps
conformationally,more similar to a CXCR4-usingenvelope, either due to
frequent recombination events between co-existing R5 and CXCR4-
using variants (Mild et al., 2007; van Rij et al., 2003), and/or to speciﬁc
adaptations of late stage viruses (both R5 and CXCR4-using variants),
thus facilitating the evolution to CXCR4 usage in the absence of the in
vivo selective pressures. These co-existing R5 variants apparently do not
evolve to CXCR4-using variants in vivo, likely due to the fact that newly
emerging, initially lowﬁt, CXCR4-using variantswill be outcompetedby
the CXCR4-using variants that are already present.
The phylogenetic tree based on gp120 envelope sequences of R5
variants and in vivo and in vitro evolved CXCR4-using variants of
patient 4 showed that in vitro evolved CXCR4-using variants were
closely related to their parental R5 variants. In vitro acquisition of
Fig. 3. Comparison of envelope molecular properties of R5 variants with or without the
ability to evolve to CXCR4-using phenotype in vitro. Net charge of the V3 region of R5
variants isolated from patients 1, 2, 3 and 4 (A). Number of Potential N-linked
Glycosylation Sites (PNGS) in gp120 (C1–C4) env region of R5 variants isolated from
patients 1, 2, 3 and 4 (B). Average net charge and average number of PNGS were
compared using a Mann–Whitney U-test. *p-values b0.05.
Table 3
Mutations in in vitro evolved CXCR4-using variants versus parental R5 variant.
Signal 
peptide
C1 V1 V2 C2 V3
AA position
Consensus B 3 28 31 51 84 140 142 140 142 146 171 227 229 231 273 275 309 312 316 317 321
gp120 region 3 2 5 30 58 8 10 12 14 15 18 34 36 38 80 82 17 20 24 25 29
RO-B2 D K
1-1 N N
RO-G1 N S T T G
3-1 · N* A* M* R
RA-H7 A S E V N T E A D F G Q
4-2 · · · · · · · · · · ·
4-3 · T K · · K · · I · ·
4-4 · · · I · · · · I · ·
4-5 V · · · ·
·
·
·
·
I* · · · L R K
4-6 · · · · · · V N I · ·
C3 V4 C4 V5 C5
AA position
Consensus B 354 355 374 387 389 396 398 400 406 427 448 449 ∆(449-450) 450 474
gp120 region 27 28 47 8 10 17 19 28 1 22 3 5 6 8 18
RO-B2 T
1-1 I*
RO-G1 T V
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the parental R5 virus, in agreement with previous reports (Chesebro
et al., 1996; Cordonnier et al., 1989; De Jong et al., 1992; Fouchier
et al., 1992, 1995; Harrowe and Cheng-Mayer, 1995; Mosier et al.,
1999; Shimizu et al., 1999; Shioda et al., 1992). Each in vitro evolved
CXCR4-using variant showed a unique mutation pattern and this
differed from the one observed in vivo, in which the only mutations
that could be associated with in vivo CXCR4 use of variants that
successfully established infection were located at positions 11 and 24
of the V3 region. This suggests that transition from CCR5 to CXCR4 use
can be achieved by multiple mutational pathways and that they are
deﬁnitely different in vitro than in vivo. The absence of host selective
pressures in the in vitro culture might have allowed for the survival of
CXCR4-using variants which would have been negatively selected in
the setting of host immune surveillance and limited target cell
availability. Indeed, as alreadymentioned above, during the transition
from CCR5 to CXCR4 usage, the virus goes through a stage of lower
ﬁtness during which the virus is less efﬁcient in coreceptor mediated
entry and highly susceptible to neutralizing antibodies (Pastore et al.,
2006). The fact that in an in vitro system based on target cell selection,
evolution from CCR5 to CXCR4 use was only observed for R5 variants
of patient 4, in combination with the lack of concordance between the
genetic pathways involved in this process in vitro and in vivo suggests
that coreceptor and target cell availability is likely not the major force
driving evolution towards CXCR4 use and underscores the role of
other host selective forces. Interestingly, none of the in vitro evolved
CXCR4-using variants could use CXCR4 in primary cells, as shown by
their inability to infect PBMC from CCR5Δ32 homozygous donors, and
2 out of 7 in vitro evolved CXCR4-using variants were unable to
replicate in theMT-2 cell-line. This probably reﬂects the low efﬁciency
by which these variants use CXCR4 given the lower expression of
CXCR4 in PBMC and MT-2 cells as compared to U87.CD4.CXCR4 cells.
As shown by Pastore et al. (2004), longer passage in vitro on U87.CD4.
CXCR4 cells may be necessary in order to acquire additional mutations
275D. Edo-Matas et al. / Virology 412 (2011) 269–277that lead to improved CXCR4 use. Moreover, CXCR4-using variants
have been reported to be more dependent on the level of CD4
expression, which is lower on primary PBMC than on U87 cells,
facilitating the emergence of CXCR4-using variants on U87 cells that
are not able to infect primary cells (Kozak et al., 1997; Platt et al.,
1998). Only one of the in vitro evolved CXCR4-using variants had one
of the V3 amino acid mutations that was exclusively present in in vivo
evolved CXCR4-using variants that successfully established infection
in peripheral blood of patient 4. This observation may indicate that,
despite the various possibilities via which the virus can acquire CXCR4
use in vitro on highly CXCR4-expressing transfected cell lines, a
speciﬁc envelope V3 amino acid composition is required to efﬁciently
use CXCR4 and successfully replicate in primary cells, as we observe in
this patient in vivo.
Conclusions
In summary, our study shows that CXCR4 use can be acquired by
certain primary R5 viruses in vitro via multiple mutational pathways.
Although mutations in the V3 region may not be an absolute
requirement for acquiring the ability to use CXCR4, they are a
prerequisite for efﬁcient CXCR4 use on primary cells and establishment
of a persisting productive infection in vivo. The possibility that these
speciﬁc amino acid changes in V3 occur only during a state of reduced
viralﬁtnessmayexplain thedelayed emergenceof CXCR4-using variants
in the natural course of HIV-1 infection; this phenotype requires the
stringent selection in vivo of initially less ﬁt transitional HIV-1 variants
that need to gain positively charged amino acids in the V3 region to
become CXCR4-using, and, constrains on other viral properties such as
replication capacity or evasion of the immune systemmay dramatically
decrease the chance of this to occur. This is in agreement with our
observations that although CCR5 to CXCR4 coreceptor evolutionmay be
attempted multiple times in vivo, the successful emergence of CXCR4-
usingvariants in vivo seems tobe the result of a unique event (Edo-Matas
et al., 2010; van Rij et al., 2000).
Materials and methods
Cells
293T cells were cultured in Dulbecco Modiﬁed Eagle's Medium
(DMEM; Lonza) supplementedwith 10% fetal calf serum(FCS; Hyclone)
and penicillin (100 U/ml; Invitrogen) and streptomycin (100 μg/ml;
Invitrogen). U87 cells expressing CD4 and CCR5 (U87.CD4.CCR5) or
CXCR4 (U87.CD4.CXCR4) were cultured in Iscove's Modiﬁed Dulbecco's
Medium (IMDM; Lonza) supplemented with 10% FCS, puromycin
(0.5 μg/ml; Invitrogen), G418 (300 μg/ml; Invitrogen), penicillin
(100 U/ml) and streptomycin (100 μg/ml). MT-2 cells were cultured
in IMDM supplemented with 10% FCS, penicillin (100 U/ml) and
streptomycin (100 μg/ml). Peripheral blood mononuclear cells
(PBMC) were isolated from buffy coats obtained from healthy HIV-1
seronegative volunteer blood donors by Lymphoprep (Fresenius Kabi
Norge) density gradient centrifugation. PBMC were cultured in IMDM
supplemented with 10% FCS, ciproxin (5 μg/ml; Bayer), phytohemag-
glutinin (PHA, 5 μg/ml; Oxoid), penicillin (100 U/ml) and streptomycin
(100 μg/ml) at a density of 5.106cells/ml. After 2 days of PHA
stimulation, the medium was replaced and PBMC cultures were
continued in IMDM supplemented with 10% FCS, ciproxin (5 μg/ml),
recombinant interleukin-2 (IL-2, 20 μg/ml; Chiron Benelux), polybrene
(5 μl/ml, hexadimethrine bromide; Sigma), penicillin (100 U/ml) and
streptomycin (100 μg/ml) at a density of 1.106cells/ml.
Viruses
Clonal HIV-1 variants from four men who have sex with men
(MSM) participants of the Amsterdam Cohort Studies on HIV/AIDS(ACS), who all developed CXCR4-using variants during the progres-
sive disease course, were used for this study (Table 1). In the ACS, the
presence of replication-competent CXCR4-using HIV-1 variants in
PBMC in all study participants at some point of their disease course is
determined by MT-2 assay on bulk PBMC (Koot et al., 1992), routinely
performed at approximately 3-monthly intervals during the entire
follow-up. The moment of ﬁrst emergence of CXCR4-using viruses
was calculated as the midpoint between the last MT-2-negative visit
and the ﬁrst MT-2-positive visit. The Amsterdam Cohort Studies are
conducted in accordance with the ethical principles set out in the
declaration of Helsinki and written informed consent was obtained
prior to data collection. The study was approved by the Academic
Medical Center institutional medical ethics committee.
Clonal HIV-1 variants were isolated from patient PBMC by co-
cultivation of serial dilution of patient PBMC with PHA stimulated
PBMC from HIV-1 seronegative donors as described previously
(Schuitemaker et al., 1992; Van 't Wout et al., 2008). Virus stocks
were grown on PHA stimulated donor PBMC. CCR5 and CXCR4 use of
clonal HIV-1 variants was determined by testing the ability of the
virus to replicate inMT-2 cells, U87CD4.CCR5 and U87.CD4.CXCR4 and
PHA stimulated PBMC homozygous for the Δ32 deletion in the CCR5
gene as described previously (De Roda Husman et al., 1999). For
patient 4, CXCR4-using clonal variants were isolated via clonal virus
isolation whilst the MT-2 test performed on bulk PBMC from the same
sample was still negative at that time point, which is most likely
related to the lower number of cells that is used for the MT-2 assay
(1×106 patient PBMC) as compared to the clonal viral isolation
procedure (up to 5×106 patients PBMC). The CCR5-using molecular
clone NL4.3-BaL (Mariani et al., 2001) was produced by transient
transfection using calcium phosphate transfection in 293T cells.
DNA isolation, PCR and sequencing
Total DNAwas isolated from 0.5 to 1×106 HIV-1 infected cells using a
modiﬁcation of the L6 isolation method (Kootstra and Schuitemaker,
1999). Gp120 env PCR ampliﬁcation was performed with PCR using
primers TB3 (fw) (5′-GGCCTTATTAGGACACATAGTTAGCC-3′) andOFM19
(rev) (5′-GCACTCAAGGCAAGCTTTATTGAGGCTTA-3′) and a nested PCR
with primers env1aTOPO (fw) (5′-CACCGGCTTAGGCATCTCCTATGGCAG-
GAAGAA-3′) and envN (rev) (5′-CTGCTAATCAGGGAAGTAGCCTTGTGT-
3′) using the expand high ﬁdelity Taq polymerase kit (Roche) and the
following ampliﬁcation cycles: 2 min30 s94 °C, 9 cycles of 15 s 94 °C, 45 s
50 °C, 6 min68 °C, 30 cycles of 15 s94 °C, 45 s 53 °C, 6 min68 °C, followed
by a 10 min extension at 68 °C and subsequent cooling to 4 °C. PCR
products were puriﬁed using ExoSAP-IT (USB) according to the
manufacturer's protocol. Sequencing of gp120 was performed using
BigDye Terminator v1.1 Cycle Sequencing kit (ABI Prism, Applied
Biosystems) according to themanufacturer's protocol using the following
ampliﬁcation cycles: 5′ at 94 °C, 30 cycles of 15″ at 94 °C, 10″ at 50 °C, 2′ at
60 °C and a 10′ extension at 60 °C and primers: Seq1 (fw) (5′-TACATAA
TGTTTGGGCCACACATGCC-3′), Seq2 (rev) (5′-TCCTTCATATCTCCTCCTC
CAGGTC-3′), Seq3 (fw) (5′-TATGGGATCAAAGCCTAAAGCCATG-3′), Seq4
(rev) (5′-CTTGTATTGTTGTTGGGTCTTGTAC-3′), Seq5 (fw) (5′-GTCAACT
CAACTGCTGTTAAATGGC-3′), Seq6 (rev) (5′-ATCTAATTTGTCCACT
GATGGGAGG-3′), env9 (rev) (5′-ACAGGCCTGTGTAATGACTGA-3′),
env1aTOPO (fw) (5′-CACCGGCTTAGGCATCTCCTATGGCAGGAAGAA-3′),
PSC (fw) (5′-CCTCAGGAGGGGACCCAG-3′), and PSH (rev) (5′-CCATAG
TGCTTCCTGCTGCT-3′).
Gp120 (C1–C4) env sequences of additional clonal HIV-1 variants
used for phylogenetic analysis were available from a separate study
(Edo-Matas et al., 2010).
In vitro evolution of CCR5-using HIV-1 towards CXCR4-use
To support the in vitro evolution towards CXCR4 coreceptor use of
R5 HIV-1 variants we used an adjusted protocol previously described
276 D. Edo-Matas et al. / Virology 412 (2011) 269–277by Pastore et al. (2004). From each CCR5-using HIV-1 variant, 1000
50% tissue culture infectious dose (TCID50) were used to inoculate
40,000 U87.CD4.CCR5 cells per well plated in a 24-well tissue culture
plate. For each virus 5–6 parallel cultures were performed. Every
week, viral replication in culture supernatant was determined in an in
house p24 capture ELISA (Tersmette et al., 1989) and p24 positive
supernatants were transferred to a fresh culture of U87.CD4.CCR5
cells. When the amount of produced p24 in the U87.CD4.CCR5 culture
was above 250 ng/ml, the supernatant was transferred to a coculture
of 10% U87.CD4.CCR5 and 90% of U87.CD4.CXCR4 cells. Every week,
the culture supernatant was transferred to fresh cocultures of U87.
CD4.CCR5 cells and U87.CD4.CXCR4 cells with decreasing percentages
of U87.CD4.CCR5 cells over time (5%, 2%, and 1% in weeks 2, 3, and 4
respectively). Subsequently, the supernatant was transferred to fresh
cultures of U87.CD4.CXCR4 cells with only 0.2% of U87.CD4.CCR5, with
transfer to fresh cocultures every week until viral replication was
detectable in the culture supernatant. Cultures that remained
negative for p24 production were continued for at least 6 weeks on
cocultures of U87.CD4.CXCR4 cells and 0.2% U87.CD4.CCR5 cells.
When virus production was detected in these cultures, the superna-
tant was transferred to fresh cultures with only U87.CD4.CXCR4 cells.
Subsequently, the in vitro evolved CXCR4-using variants were
analyzed for their ability to infect MT-2 cells, U87.CD4.CCR5 cells
and PHA stimulated PBMC homozygous for the Δ32 deletion in the
CCR5 gene as described previously (De Roda Husman et al., 1999).
Phylogenetic analysis
Nucleotide sequences were aligned using ClustalW in the software
package of BioEdit v.7.0.9 (Hall, 1999) and edited manually.
Cross-contamination between samples from the four study
subjects was excluded using phylogenetic analysis (Edo-Matas et al.,
2010).
The best-ﬁt nucleotide substitution model for the alignment of
clonal HIV-1 variants and in vitro evolved CXCR4-using variants gp120
(C1–C4) env sequences from patient 4 was selected by hierarchical
likelihood ratio test (hLTR) in Model Test 3.7 (Posada and Crandall,
1998) and implemented in the construction of maximum likelihood
(ML) tree. The heuristic search for the best tree was performed using a
NJ tree as starting tree and the TBR branch-swapping algorithm. NJ
trees were constructed under the HKY85 model with a transition/
transversion ratio and the shape of the γ-distribution estimated using
maximum likelihood. ML tree was rooted using the root that
maximized the correlation of root-to-tip divergence as a function of
sampling time and edited with FigTree (http://tree.bio.ed.ac.uk/
software/ﬁgtree/).
Analysis of envelope molecular properties
Potential N-linked Glycosylation Sites (PNGS) were identiﬁed
using N-Glycosite (Zhang et al., 2004) at the HIV database website
(http://www.hiv.lanl.gov/content/sequence/GLYCOSITE/glycosite.
html). Charge was calculated by counting all charged amino acid
residues per sequence, where R and K were counted as +1, H as
+0.293, and D and E as −1. Average charge and average number of
PNGS were compared using a Mann–Whitney U test in GraphPad
Prism version 5.00 for Windows.
Supplementarymaterials related to this article can be found online
at doi:10.1016/j.virol.2011.01.010.
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